A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
Randomized phase III, double-blind, placebo-controlled, multicenter clinical trial.
Lung Cancer
DRUG: Canakinumab|DRUG: Placebo
Time To Lung Cancer, TTLC will be measured from the date of randomization up to the date of lung cancer or, for subjects free from disease, the date of last contact., date of randomization up to the date of lung cancer or, for subjects free from disease, the date of last contact, up to 48 months
Time to Lung cancer death, Time to Lung cancer death, date of randomization, up to 48 months|Overall Survival (OS), Overall Survival (OS), date of randomization, up to 48 months|cancer mortality, cancer mortality, date of randomization, up to 48 months|shrinkage of non-solid nodules, shrinkage of non-solid nodules, date of randomization, up to 48 months|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, date of randomization, up to 48 months
This is a multicentre, randomized, stratified, double-blind, placebo controlled, phase III study in subjects at high risk of lung cancer with hs CRP\>3 mg/L undergoing annual screening low dose CT.

The Sponsor anticipate to screen some 6.000 subjects, of whom about 700 will be recruited and evaluated in the randomized phase 3 trial.

Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.